ABSTRACT
INTRODUCTION: Despite multidrug therapy, leprosy remains a public health issue. The intradermal Bacillus Calmette-Guérin (BCG) vaccine, Mitsuda test (lepromin skin test), and anti-phenolic glycolipid I (PGL-I) serology are widely used in leprosy studies and have shown great epidemiological value. METHODS: This longitudinal study evaluated the relative risks and benefits of these three tools by comparing results observed in household contacts (HHCs) of leprosy patients who developed leprosy with those of HHCs who did not in a population of 2,992 individuals monitored during a 10-year period. RESULTS: Seventy-five (2.5%) new leprosy cases were diagnosed, including 28 (0.9%) co-prevalent cases. Therefore, for the risk-benefit assessment, 47 (1.6%) HHCs were considered as truly diagnosed during follow-up. The comparison between healthy and affected contacts demonstrated that not only did BCG vaccination increase protection, but boosters also increased to 95% relative risk (RR) reduction when results for having two or more scars were compared with having no scars [RR, 0.0459; 95% confidence interval (CI), 0.006-0.338]. Similarly, Mitsuda reactions >7mm in induration presented 7-fold greater protection against disease development compared to reactions of 0-3mm (RR, 0.1446; 95% CI, 0.0566-0.3696). In contrast, anti-PGL-I ELISA seropositivity indicated a 5-fold RR increase for disease outcome (RR, 5.688; 95% CI, 3.2412-9.9824). The combined effect of no BCG scars, Mitsuda reaction of <7mm, and seropositivity to anti-PGL-I increased the risk for leprosy onset 8-fold (RR, 8.109; 95% CI, 5.1167-12.8511). CONCLUSIONS: The adoption of these combined assays may impose measures for leprosy control strategies.
Subject(s)
Antigens, Bacterial/immunology , BCG Vaccine/immunology , Contact Tracing/statistics & numerical data , Glycolipids/immunology , Leprosy/immunology , Adolescent , Adult , Aged , Child , Child, Preschool , Enzyme-Linked Immunosorbent Assay , Female , Humans , Infant , Infant, Newborn , Lepromin/immunology , Leprosy/prevention & control , Leprosy/transmission , Longitudinal Studies , Male , Middle Aged , Risk Assessment , Young AdultABSTRACT
Abstract: INTRODUCTION: Despite multidrug therapy, leprosy remains a public health issue. The intradermal Bacillus Calmette-Guérin (BCG) vaccine, Mitsuda test (lepromin skin test), and anti-phenolic glycolipid I (PGL-I) serology are widely used in leprosy studies and have shown great epidemiological value. METHODS: This longitudinal study evaluated the relative risks and benefits of these three tools by comparing results observed in household contacts (HHCs) of leprosy patients who developed leprosy with those of HHCs who did not in a population of 2,992 individuals monitored during a 10-year period. RESULTS : Seventy-five (2.5%) new leprosy cases were diagnosed, including 28 (0.9%) co-prevalent cases. Therefore, for the risk-benefit assessment, 47 (1.6%) HHCs were considered as truly diagnosed during follow-up. The comparison between healthy and affected contacts demonstrated that not only did BCG vaccination increase protection, but boosters also increased to 95% relative risk (RR) reduction when results for having two or more scars were compared with having no scars [RR, 0.0459; 95% confidence interval (CI), 0.006-0.338]. Similarly, Mitsuda reactions >7mm in induration presented 7-fold greater protection against disease development compared to reactions of 0-3mm (RR, 0.1446; 95% CI, 0.0566-0.3696). In contrast, anti-PGL-I ELISA seropositivity indicated a 5-fold RR increase for disease outcome (RR, 5.688; 95% CI, 3.2412-9.9824). The combined effect of no BCG scars, Mitsuda reaction of <7mm, and seropositivity to anti-PGL-I increased the risk for leprosy onset 8-fold (RR, 8.109; 95% CI, 5.1167-12.8511). CONCLUSIONS: The adoption of these combined assays may impose measures for leprosy control strategies.
Subject(s)
Adolescent , Adult , Aged , Child , Child, Preschool , Female , Humans , Infant , Infant, Newborn , Male , Middle Aged , Young Adult , Antigens, Bacterial/immunology , BCG Vaccine/immunology , Contact Tracing/statistics & numerical data , Glycolipids/immunology , Leprosy/immunology , Enzyme-Linked Immunosorbent Assay , Longitudinal Studies , Lepromin/immunology , Leprosy/prevention & control , Leprosy/transmission , Risk AssessmentABSTRACT
BACKGROUND AND OBJECTIVE: Multidrug therapy in leprosy has failed to eliminate the problem of persister bacilli. Clearance of bacterial antigens is extremely slow which could predispose to continued nerve damage even after release from treatment. In the present study the immunomodulatory efficacy of BCG vaccine administered post-MDT in BL-LL leprosy patients was investigated in depth with a view to determining if augmenting chemotherapy with immunotherapy would help in faster clearance of M. leprae/antigens, bring down the level of persisters and minimise the occurrence/severity of reaction and nerve damage. METHODS: This is a placebo-controlled study in treated BL-LL patients. The patients are matched with respect to age, sex, bacteriological index and history of reaction, stratified and allocated to the two groups. One group (Gr A) received two doses of BCG-MOSCOW (3-33 x 10(5) cells) and the other (Gr B) normal saline (0.85%), injected intra-dermally at 3 month intervals. The Primary outcomes assessed at the end of 6 months were bacterial/antigen clearance, lepromin conversion, granuloma clearance and the occurrence of persisters. The secondary outcomes were clinical regression, occurrence and severity of reaction and changes in nerve functions. MATERIAL: A total of 107 BL-LL patients comprised of 49 in Gr A and 58 in Gr B; of which 36 and 42 respectively completed the study as per protocol, and are included in the final analysis. FINDINGS: The study findings show that both the primary and the secondary out comes were comparable in the two groups. Two doses of BCG administered post-MDT (Gr A) did not significantly alter the level of persisters or help in hastening the bacterial/antigen clearance, clinical regression of lesions and granuloma clearance. Lepromin conversion rates were also comparable. While the frequency of lepra reaction/neuritis following the intervention was comparable, the severity of reactions was significantly higher in Gr A. On the positive side neural functions assessed by nerve conduction studies showed that deterioration of motor nerve conduction was significantly lower in the BCG arm. Since all patients developing moderate to severe reactions, immediately received a course of corticosteroids, it is possible that timely use of it might have helped.
Subject(s)
BCG Vaccine/therapeutic use , Lepromin/immunology , Leprostatic Agents/therapeutic use , Leprosy/drug therapy , Leprosy/immunology , Mycobacterium leprae/immunology , Nerve Tissue/physiology , Adolescent , Adult , BCG Vaccine/adverse effects , Drug Therapy, Combination , Female , Humans , Immunotherapy , Leprosy/microbiology , Male , Middle Aged , Nerve Tissue/drug effects , Young AdultABSTRACT
BACKGROUND: An early diagnostic test for detecting infection in leprosy is fundamental for reducing patients' sequelae. The currently used lepromin is not adequate for disease diagnosis and, so far, no antigen to be used in intradermoreaction has proved to be sensitive and specific for that purpose. Aiming at identifying new reagents to be used in skin tests, candidate antigens were investigated. METHODS: Random peptide phage display libraries were screened by using antibodies from leprosy patients in order to identify peptides as diagnostic reagents. RESULTS: Seven different phage clones were identified using purified antibodies pooled from sera of leprosy patients. When the clones were tested with serum samples by ELISA, three of them, 5A, 6A and 1B, allowed detecting a larger number of leprosy patients when compared to controls. The corresponding peptides expressed by selected phage clones were chemically synthesized. A pilot study was undertaken to assess the use of peptides in skin tests. The intradermal challenge with peptides in animals previously sensitized with Mycobacterium leprae induced a delayed-type hypersensitivity with peptide 5A (2/5) and peptide 1B (1/5). In positive controls, there was a 3/5 reactivity for lepromin and a 4/5 reactivity of the sensitized animals with soluble extract of M. leprae. CONCLUSIONS: The preliminary data suggest that may be possible to develop reagents with diagnostic potential based on peptide mimotopes selected by phage display using polyclonal human antibodies.
Subject(s)
Antigens, Bacterial/immunology , Leprosy/diagnosis , Mycobacterium leprae/immunology , Animals , Cell Surface Display Techniques , Epitopes/immunology , Female , Guinea Pigs , Humans , Hypersensitivity, Delayed/immunology , Lepromin/immunology , Peptide Library , Peptides/immunologySubject(s)
Antigens, Bacterial/immunology , Lepromin/immunology , Leprosy/diagnosis , Skin Tests , History, 20th Century , HumansABSTRACT
Delayed Type Hypersensitivity (DTH) and protective immunity are thought to be tightly linked. Remarkable similarity exists between their cellular and immune mechanisms. However, their dissociation is also well known. Here we investigate the immunological mechanisms relevant for their dissociation in a group of non-relapsing cured lepromatous leprosy (CLL) patients. In these patients, using lepromin reaction as a model system of DTH we report critical role of tissue chemokine response in synchronous manifestation of these linked phenomena. Results indicate elevation of the threshold of tissue chemokine induction thus dissociating DTH from protective immunity in lepromin -ive CLL patients. We also show that the DTH anergy in these subjects is not an absolute one but depends on the strength of the stimulus. Our data provide insights into the intricate relationship between DTH and immunity and highlight the persistent presence of effector immune mechanisms involving these two pathways in apparently unresponsive lepromatous leprosy patients.
Subject(s)
Chemokines/immunology , Hypersensitivity, Delayed/immunology , Lepromin/immunology , Leprosy, Lepromatous/immunology , T-Lymphocytes/immunology , Chemokines/metabolism , Humans , Immunity/immunology , Leprosy, Lepromatous/microbiology , Lymphocyte Activation , Mycobacterium leprae/immunologyABSTRACT
Hypersensitivity reactions called reversal reaction (RR) and erythema nodosum leprosum (ENL) occur in leprosy. They are characterized by an increase in tumor necrosis factor-alpha (TNF-alpha). Thalidomide is an effective treatment for ENL but not RR. Its effectiveness in ENL is attributed to inhibition of TNF-alpha, and this does not explain its failure to treat RR. We assessed thalidomide's effect on TNF-alpha in RR. Mononuclear cells from RR and non-RR patients and healthy individuals were treated with thalidomide and M.leprae (AFB), a cytosol fraction of M. leprae or Dharmendra lepromin. Thalidomide suppressed TNF-alpha, but when some RR patients' cells were stimulated with AFB, it enhanced TNF-alpha.
Subject(s)
Leukocytes, Mononuclear/drug effects , RNA, Messenger/metabolism , Thalidomide/pharmacology , Tumor Necrosis Factor-alpha/biosynthesis , Adolescent , Adult , Aged , Antigens, Bacterial/immunology , Antigens, Bacterial/pharmacology , Cell Proliferation/drug effects , Cell Survival/drug effects , Cells, Cultured , Erythema Nodosum/drug therapy , Erythema Nodosum/etiology , Erythema Nodosum/immunology , Female , Humans , Lepromin/immunology , Lepromin/pharmacology , Leprosy/blood , Leprosy/complications , Leprosy/pathology , Leukocytes, Mononuclear/cytology , Leukocytes, Mononuclear/metabolism , Lymphocyte Activation/drug effects , Male , Middle Aged , Mycobacterium leprae/immunology , Phytohemagglutinins/pharmacology , RNA, Messenger/genetics , Reverse Transcriptase Polymerase Chain Reaction/methods , Tumor Necrosis Factor-alpha/geneticsABSTRACT
Controversies over the vitamin D receptor (VDR) acting as a susceptibility factor in Mycobacterium sp. infections may be the result of incorrect population stratification. The risk of leprosy occurrence conditioned by VDR polymorphism was investigated by stratifying the population of a highly endemic Brazilian region into negative and positive Mitsuda responses. Leprosy patients (102) and a group of healthy nonconsanguineous household contacts (68) were genotyped for the VDR TaqI polymorphism (T/t). TT and Tt genotypes were not considered to be risk factors as their odds ratios (OR) were not different from those presented by the negative Mitsuda response individuals. The combination of the tt genotype and the negative Mitsuda test provided an occurrence rate 13 times higher in leprosy patients than in controls with positive Mitsuda responses. This suggests that there is a higher risk of leprosy development when individuals carry this unfavorable combination, and demonstrates a possible synergistic role of these two variables in leprosy susceptibility via effects on cellular immunity.
Subject(s)
Lepromin/immunology , Leprosy/genetics , Polymorphism, Genetic , Receptors, Calcitriol/genetics , Exons/genetics , Genetic Predisposition to Disease/genetics , Genotype , Humans , Leprosy/immunology , Leprosy/physiopathology , Mycobacterium leprae/immunology , Skin/immunologyABSTRACT
The Leprosy Control Program of Antioquia, (post-elimination leprosy state of Colombia), had registered by 1999, 56 lepromatous leprosy patients and their household contacts (HHC). Our interest was to detect Mycobacterium leprae infection in these HHC. Clinical examination, acid-fast bacillary staining (AFB) in nasal secretions, and slit skin samples, IgM anti-PGL-I in serum and Lepromine A (Mitsuda) reactivity were tested. Two hundred forty eight HHC were studied, 49 percent were male. After clinical examination, two HHC were diagnosed as multi bacillary patients; 13 percent showed positive IgM anti-PGL-I titers; Mitsuda reaction (> 4 mm) was positive in 59 percent; AFB was negative in all samples, except in the two new patients. HHC were classified according to test results.Group 1: two new multi bacillary patients. Group 2: 15 HHC seropositive, Mitsuda-negative. Group 3: 13 HHC seropositive, Mitsuda-positive. Group 4: 130 HHC seronegative, Mitsuda-positive. Group 5: 88 HHC seronegative, Mitsuda-negative. These results are an indication that the transmission of the infection is still happening in a region considered in the post elimination phase. The two new patients represent an infection source for others contacts, and groups 2 and 3 are infected HHC that could develop the disease in future. Follow up of high risk population is necessary to achieve real elimination of leprosy.
Subject(s)
Child, Preschool , Child , Adolescent , Adult , Middle Aged , Aged, 80 and over , Humans , Male , Female , Antibodies, Bacterial/blood , Antigens, Bacterial/blood , Glycolipids/blood , Lepromin/immunology , Leprosy, Lepromatous/diagnosis , Mycobacterium leprae/immunology , Cross-Sectional Studies , Colombia/epidemiology , Enzyme-Linked Immunosorbent Assay , Intradermal Tests , Immunoglobulin G/blood , Leprosy, Lepromatous/epidemiology , Leprosy, Lepromatous/transmission , Risk FactorsABSTRACT
A 22-year-old male polar lepromatous leprosy patient who became Mitsuda positive after 36 months of multidrug therapy (MDT) is reported. Lepromatous leprosy (LL) is a state of specific immunosuppression and is invariably irreversible. The finding of Mitsuda positivity in histopathologically proven polar lepromatous leprosy is extremely uncommon, and conversion of lepromin status following MDT has not so far been reported. This case reports confirms the observations made by Waters et al. regarding lepromin conversion in lepromatous patients.
Subject(s)
Immunocompromised Host , Lepromin/immunology , Leprostatic Agents/therapeutic use , Leprosy, Lepromatous/immunology , Adult , Drug Therapy, Combination , Humans , Leprosy, Lepromatous/drug therapy , MaleABSTRACT
BACKGROUND: Leprosy is a chronic infectious disease caused by Mycobacterium leprae. The Mitsuda reaction is a delayed granulomatous skin reaction elicited by intradermal injection of heat-killed M. leprae. Interestingly, results of the Mitsuda test are positive in the majority of individuals, even in areas not endemic for M. leprae. Like leprosy, the Mitsuda reaction is thought to be genetically controlled, but its mode of inheritance is unknown, although the role of the NRAMP1 gene has previously been reported. METHODS: We conducted a segregation analysis of quantitative Mitsuda reactivity in 168 Vietnamese nuclear families ascertained through patients with leprosy. RESULTS: We found strong evidence (P<10-9) for a major gene controlling the Mitsuda reaction independently of leprosy clinical status. Subsequent linkage analysis showed that this major gene was distinct from NRAMP1. Under the major-gene model, approximately 12% of individuals are homozygous for the recessive predisposing allele and are predicted to display high levels of Mitsuda reactivity (mean, approximately 10 mm, versus 5 mm in other individuals). CONCLUSION: We provide evidence that the Mitsuda reaction is controlled by a major gene. Our study paves the way for the identification of this gene and should provide novel insight into the mechanisms involved in granuloma formation, especially in M. leprae infection.
Subject(s)
Genetic Predisposition to Disease , Lepromin/immunology , Leprosy/epidemiology , Mycobacterium leprae/genetics , Skin/immunology , Female , Genes, Recessive , Haplotypes , Humans , Injections, Intradermal , Leprosy/genetics , Leprosy/immunology , Leprosy, Lepromatous/immunology , Leprosy, Tuberculoid/epidemiology , Leprosy, Tuberculoid/genetics , Leprosy, Tuberculoid/immunology , Male , VietnamABSTRACT
The Leprosy Control Program of Antioquia, (post-elimination leprosy state of Colombia), had registered by 1999, 56 lepromatous leprosy patients and their household contacts (HHC). Our interest was to detect Mycobacterium leprae infection in these HHC. Clinical examination, acid-fast bacillary staining (AFB) in nasal secretions, and slit skin samples, IgM anti-PGL-I in serum and Lepromine A (Mitsuda) reactivity were tested. Two hundred forty eight HHC were studied, 49% were male. After clinical examination, two HHC were diagnosed as multi bacillary patients; 13% showed positive IgM anti-PGL-I titers; Mitsuda reaction (> or = 4 mm) was positive in 59%; AFB was negative in all samples, except in the two new patients. HHC were classified according to test results. Group 1: two new multi bacillary patients. Group 2: 15 HHC seropositive, Mitsuda-negative. Group 3: 13 HHC seropositive, Mitsuda-positive. Group 4: 130 HHC seronegative, Mitsuda-positive. Group 5: 88 HHC seronegative, Mitsuda-negative. These results are an indication that the transmission of the infection is still happening in a region considered in the post elimination phase. The two new patients represent an infection source for others contacts, and groups 2 and 3 are infected HHC that could develop the disease in future. Follow up of high risk population is necessary to achieve real elimination of leprosy.
Subject(s)
Antibodies, Bacterial/blood , Antigens, Bacterial/blood , Glycolipids/blood , Lepromin/immunology , Leprosy, Lepromatous/diagnosis , Mycobacterium leprae/immunology , Adolescent , Adult , Aged , Aged, 80 and over , Child , Child, Preschool , Colombia/epidemiology , Cross-Sectional Studies , Enzyme-Linked Immunosorbent Assay , Female , Humans , Immunoglobulin G/blood , Intradermal Tests , Leprosy, Lepromatous/epidemiology , Leprosy, Lepromatous/transmission , Male , Middle Aged , Risk FactorsABSTRACT
Controversial results have been achieved by attempting to associate the NRAMP1 gene with Mycobacterium leprae susceptibility as well as with the Mitsuda reaction, which represents a specific immune response to M. leprae. This study evaluated this association as well as the interaction of the polymorphism (GT)(n) in the promoter region of the NRAMP1 gene with a specific immune response to M. leprae measured by the intradermal Mitsuda test in leprosy patients and in non-consanguineous household contacts. The study aimed to evaluate the association of this gene polymorphism with resistance or susceptibility to the disease, and/or with clinical forms of the disease, in a population in an endemic area served by the State Reference Center in Sanitary Dermatology and Leprosy, Federal University of Uberlandia, MG, Brazil. Leprosy patients (90) were diagnosed according to Ridley and Jopling criteria and they grouped into multibacillary (MB) and paucibacillary (PB) patients. The control group consisted of 61 non-consanguineous contacts. NRAMP1 promoter genotypes were obtained through amplification by the polymerase chain reaction (PCR) followed by the detection through the low ionic-strength single strand conformational polymorphism (LIS-SSCP) electrophoretic technique. There were no significant differences in the allelic and genotypic frequencies for alleles 2, 3, and 4 in relation to the Mitsuda test among patients and household contacts, nor between those with MB and PB forms. However, individuals with a negative lepromin response associated with genotypes 22 and 23 presented a 7- and 8-fold greater chance of developing leprosy, respectively. Therefore, the NRAMP1 gene promoter polymorphism exhibited an interaction with the lepromin response, suggesting that allele 2 of the NRAMP1 promoter is an independent genetic factor that predisposes cells to enable pathogen survival, probably due to its low efficiency in iron transport. However, establishment of the infection and disease development may be conditioned by other immunological and genetic factors.
Subject(s)
Cation Transport Proteins/genetics , Genetic Predisposition to Disease , Lepromin/immunology , Leprosy/genetics , Polymorphism, Genetic , Promoter Regions, Genetic , Alleles , Family , Gene Frequency , Humans , Leprosy/immunology , Mycobacterium leprae/immunology , Polymerase Chain Reaction , Polymorphism, Single-Stranded Conformational , Skin/immunologyABSTRACT
This is a retrospective study of 276 patients consisting of 157 active and 119 reactive patients of borderline leprosy. They were followed up for 10 years after sulphone monotherapy. The presenting symptoms were carefully examined from the records and systematically presented. Frequency of reactions was least in BT cases and most in BL cases. Risk factors of reaction appear to be the type of leprosy, multiplicity of lesions, high BI and, possibly, psychological stress. Biopsy of skin lesions was performed in all cases initially, and at the subsidence of the disease. Histological findings closely correlated with clinical classification. While all the cases showed clinical subsidence, histological subsidence was found in 200 (73%) cases, and the condition was static in 36 cases (13%). Immunological upgrading was seen in 110%, while 4% showed downgrading. Bacteriological status and lepromin reaction of active and reactive cases were compared. All these factors need to be taken into consideration for instituting prompt and proper treatment.
Subject(s)
Leprosy, Borderline/pathology , Leprosy, Lepromatous/pathology , Leprosy, Tuberculoid/pathology , Mycobacterium leprae/growth & development , Biopsy , Disease Progression , Erythema/immunology , Erythema/pathology , Female , Follow-Up Studies , Humans , Lepromin/immunology , Leprosy, Borderline/drug therapy , Leprosy, Borderline/immunology , Leprosy, Lepromatous/drug therapy , Leprosy, Lepromatous/immunology , Leprosy, Tuberculoid/drug therapy , Leprosy, Tuberculoid/immunology , Male , Peripheral Nerves/immunology , Peripheral Nerves/pathology , Retrospective StudiesABSTRACT
Se llevó a cabo una vacunación a dosis única con Mycobactericem habana, con 31 casos de lepra lepromatosa que recibieron 1-5 mg (1'5 mg = 6'27 x 108 bacilos) y 36 convivientes con 1'5, 2'0, 2'5 mg de vacuna intradérmica. La du ración del estudio fue de 18 semanas. La vacunación indujo conversión a la lepromina en el 100 por ciento de los casos lepromatosos y convivientes de lepromina negativos y aumento del 100 por ciento en contactos lepromina positivos, estable durante las 15 semanas de duración del seguimiento, El incremento máximo en la reactividad a la lepromina se obtuvo con 1'5 mg de vacuna, probablemente la dosis máxima admisible. Además, la vacunación de los no vacuna BCG previa reveló un valor promedio superior de incremento de la lepromina. Los cambios en la vacunación local incluyen induración, ulceración, picazón dolorosa y linfodenopatías periféricas, todas remitieron espontáneamente a las 15 semanas. Los efectos secundarios sistémicos resultaron ser pyrexia, ENL, ictericia con una frecuencia no superior a lo observado con otras vacunas. Estos efectos secundarios sistémicos eran fácilmente controlables y no se acompañaban de deterioro ocular o nervioso. Las investigaciones analíticas tipo perfil de seguridad, revelaron un incremento en el valor promedio de la cantidad de (hemoglobina) Hb por ciento, RBC (hematíes) y PCV en los convivientes y de PCV en pacientes lepromatosos, post-vacunación. También se observaron alteraciones en las funciones hepáticas en los pacientes con lepra lepromatosa. Por lo tanto, M. habana parece útil en estimular CMI específica contra M. leprae como evidencia la reactividad incrementada a la lepromina (AU)
Subject(s)
Female , Male , Humans , Mycobacterium leprae/immunology , Leprosy, Lepromatous/prevention & control , Bacterial Vaccines/administration & dosage , Cuba , Pilot Projects , Follow-Up Studies , Efficacy , Lepromin/immunology , Lepromin/analysisABSTRACT
Thirty sib-pairs were ascertained through unrelated lepromatous probands. They consisted of 22 healthy individuals and 8 leprosy patients. The Mitsuda reactions of all sibs were evaluated both macroscopically and histologically, and high molecular weight genomic DNA was extracted from the white blood cells of all sib-pairs. Three DNA polymorphisms identified by polymerase chain reaction (274C/T, D543N, 1729 + 55del4) were used as chromosome markers at the NRAMP1 locus. Sib-pair comparisons did not disclose any sign of close linkage between the Mitsuda reaction and the genetic markers.
Subject(s)
Lepromin/genetics , Lepromin/immunologyABSTRACT
A total of 20 bacteriologically positive multibacillary (MB) leprosy patients older than 18 years of age with a bacterial index (BI) of 2+ or greater were given standard World Health Organization multiple drug therapy (MDT-MB) for 12 consecutive months plus four intradermal doses of Mycobacterium w vaccine at 3 monthly intervals (Study group). Twenty age-matched MB patients were given WHO/MDT alone (Control group). The patients of both groups were followed up for 1 year. Improvements in the patients were periodically monitored by clinical (Ramu's score), bacteriological (SSS), histopathological (skin biopsy) and immunological (lepromin conversion) parameters. Study group patients showed more significant improvements in all parameters except for lepromin conversion compared to patients in the Control group. The incidence of type 1 reaction was more in the Study group (30% vs 10%), while the incidence of type 2 reaction was more in the Control group (25% vs 15%). Neuritis associated with reactions was seen more often in the Control group compared to the Study group (20% vs 10%). The addition of Mycobacterium w vaccine as an adjunct to the 1-year WHO/MDT regimen appears to be significantly more beneficial in MB leprosy patients with a high initial BI compared to WHO/MDT given alone. Studies on larger numbers of patients with extended follow up will be in order.
Subject(s)
Bacterial Vaccines/therapeutic use , Leprosy/therapy , Mycobacterium leprae/immunology , Adult , Bacterial Vaccines/immunology , Biopsy , Drug Combinations , Female , Histocytochemistry , Humans , Lepromin/immunology , Leprosy/immunology , Male , World Health OrganizationABSTRACT
The immune responses of 19 treated lepromatous patients who had remained smear negative for a long period were assessed for specific cell-mediated immunity (CMI), anti-Mycobacterium leprae antibodies and cytokine release in response to challenge with M. leprae soluble antigen (MLSA). All of these patients remained anergic to Mitsuda lepromin. Lymphoproliferation in response to M. leprae antigen was noted in only two patients. Significant reduction in the phenolic glycolipid I (PGL-I) antibody response in treated patients with no difference in the M. leprae 35-kDa antibody response was observed when these responses were compared with those of active lepromatous patients. More treated patients produced interleukin-2 (IL-2) and interferon gamma (IFN-gamma) than did active patients. On the other hand, fewer treated patients produced IL-10 than did active patients. These limited findings suggest that the host immune response makes an attempt toward upregulation of CMI in some treated LL/BL patients.
Subject(s)
Antigens, Bacterial , Leprosy, Lepromatous/immunology , Mycobacterium leprae/immunology , Adult , Aged , Antibodies, Bacterial/biosynthesis , Antibodies, Bacterial/blood , Cytokines/biosynthesis , Cytokines/blood , Enzyme-Linked Immunosorbent Assay , Female , Glycolipids/immunology , Humans , Hypersensitivity, Delayed/immunology , Lepromin/immunology , Leprosy, Lepromatous/blood , Leprosy, Lepromatous/drug therapy , Lymphocyte Activation/immunology , Male , Middle AgedABSTRACT
The Ridley-Jopling system of classification of the variegated clinical pattern of leprosy is based on the specific cell-mediated immunity observed in the histopathology of skin lesions conforming to a spectrum from TT at one end to LL at the other. In this study a fairly large sample of 90 patients was classified on clinical grounds; the histopathology of the skin lesions was studied blind. There was an overall concordance of 90% between the clinical and histological classifications. In addition, the systemic cell-mediated and humoral immune responses were studied. The in vivo cell-mediated immune response, namely the Mitsuda skin response, mostly conformed to the clinical classification. While the in vitro lymphoproliferative responses to BCG and its sonicate were high, the lymphoproliferative responses to Dharmendra lepromin were surprisingly poor. Humoral responses to 35 kDA protein of M. leprae and PGL-1 were good in most LL, BL patients and tapered off towards TT. IgG antibodies to recombinant ML 65 kDa proteins denoted mycobacterial presence.
Subject(s)
Leprosy/classification , Adult , Antibody Formation , Female , Humans , Immunity, Cellular , Lepromin/immunology , Leprosy/immunology , Leprosy/pathology , Lymphocyte Activation , Male , Mycobacterium leprae/immunology , Skin/pathologyABSTRACT
In 14 nine-banded armadillos the Mitsuda response to nude mouse-derived lepromin (lepromin-nu/nu) was compared to that of armadillo-derived lepromin (lepromin-A) by injecting the reagents intradermally into either side of the abdomen of the animal and examining the biopsies from the sites after 12 days. The histopathologic responses to both antigens were found to be similar, whether the animal was Mitsuda-negative (lepromatous) or Mitsuda-positive (tuberculoid). It is pointed out that armadillos are good experimental models for leprosy, and their use can replace humans in experimental studies.